Novartis stock recovers after trial setbacks as analysts lift earnings outlook
Published on 09/14/2026 at 14:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novartis AG (ISIN CH0012005267) stock showed signs of recovery on September 14, 2026, with its primary listing on SIX Swiss Exchange trading around 115.10 CHF intraday after a volatile stretch triggered by late-stage trial failures and a sharp drop in market value.
Trial failures hit valuation but guidance and pipeline remain in focus
According to Genetic Engineering & Biotechnology News on September 13, 2026, Novartis lost roughly USD 30 billion in market capitalization over the past week after its neuromuscular candidate delpacibart etedesiran, also known as del-desiran, failed a Phase III trial, sending SIX-listed shares down 11 percent in one session from 125.46 CHF to 111.80 CHF and New York-listed ADRs down 14 percent from USD 159.99 to USD 137.72.
As Yahoo Finance reported on September 13, 2026, Novartis had already announced on September 4, 2026 that pelacarsen, its Lp(a)-lowering therapy, missed the primary composite endpoint of cardiovascular events in the Phase 3 Lp(a)HORIZON trial, a negative readout that reverberated across the cardiovascular-drug sector.
Previous-week trading data compiled by Genetic Engineering & Biotechnology News show that despite the selloff, Novartis primary shares on SIX had still risen about 2 percent year-to-date from 108.50 CHF and about 11 percent year-over-year from 101.78 CHF, indicating that the long-term performance remains positive even after the recent correction.
Stock price, 52-week high and market cap signal room for recovery
Per data from finanzen.ch on September 14, 2026, Novartis shares on SIX Swiss Exchange gained 2.7 percent at 12:28 p.m. local time to trade at 115.10 CHF, after opening the session at 113.20 CHF and reaching an intraday high of 115.12 CHF.
The same trading overview from finanzen.ch notes that Novartis shares reached a 52-week high of 132.68 CHF on September 3, 2026, so the current level of about 115.10 CHF leaves a gap of roughly 17.6 CHF or around 13.3 percent to that recent peak, underscoring that the stock is trading below its early-September high yet still within the upper portion of its one-year range.
According to the New York-traded ADR snapshot on MarketBeat as of the closing price on September 11, 2026, the ADRs closed at USD 137.22, with a 52-week range between USD 121.57 and USD 170.46 and a market capitalization of about USD 261.84 billion, implying that U.S.-listed Novartis stock is also trading about USD 33.24 or roughly 19.5 percent below its 52-week high while still far above the annual low.
Analysts lift EPS estimates and maintain a Hold consensus
In spite of the recent clinical setbacks, earnings expectations have edged higher: according to MarketBeat on September 14, 2026, Erste Group Bank analyst H. Engel raised their FY2026 earnings-per-share estimate for Novartis to USD 8.99 from a prior USD 8.95, while the consensus full-year EPS forecast across analysts stands at about USD 8.85.
The same analyst compilation from MarketBeat indicates that six equity research analysts currently rate Novartis stock Buy and ten rate it Hold, yielding a consensus rating of Hold and an average price target of USD 153.00 for the ADR, about USD 15.78 or roughly 11.5 percent above the recent opening price of USD 137.22 used in the calculation.
Detailed consensus data on MarketBeat show a price-target range for Novartis between a high of USD 180.00 and a low of USD 126.00, a consensus target of USD 153.00 and about 11.5 percent implied upside from the current ADR level of USD 137.22, reflecting that many analysts see scope for medium-term recovery despite the recent downturn.
Investor implications and upcoming earnings expectations
In addition to the Erste Group Bank revision, expert commentary compiled by finanzen.ch on September 14, 2026 suggests that analysts expect Novartis to earn about USD 8.80 per share in 2026, a figure close to the wider consensus of USD 8.85 cited by MarketBeat and slightly below Erste Group Bank's more optimistic USD 8.99 forecast, illustrating a relatively tight range of earnings expectations that can serve as an anchor for valuation discussions.
Recent share-performance analysis from Genetic Engineering & Biotechnology News highlights that Novartis SIX-listed shares ended the prior week at 112.04 CHF and ADRs at USD 137.16, so the rebound to around 115.10 CHF on September 14, 2026 and the ADR holding near USD 137-levels suggest that the initial shock has eased but the stock has not yet reclaimed the prices seen before the del-desiran and pelacarsen trial announcements.
For investors, the key near-term risk remains further clinical news from Novartis pipeline programs that could either restore confidence if positive or prolong uncertainty if additional late-stage failures occur, while the upside case rests on the company meeting or beating the EPS forecasts around USD 8.80 to USD 8.99 for 2026 and gradually closing the roughly 13 to 20 percent gap between current prices and the respective 52-week highs in Zurich and New York.
Novartis stock price snapshot on SIX Swiss Exchange
At midday on September 14, 2026, Novartis stock on its primary listing at SIX Swiss Exchange was quoted at about 115.10 CHF, up 2.7 percent on the day from an opening level of 113.20 CHF and within a 52-week range that peaked at 132.68 CHF on September 3, 2026, illustrating that the shares have recovered part of the recent selloff but still trade materially below their early-September high.
Novartis stock key data
- Company: Novartis AG
- ISIN: CH0012005267
- Ticker: NOVN
- Trading venue: SIX Swiss Exchange
- Price (as of September 14, 2026, 12:28): 115.10 CHF
- Market capitalization: 261,840,000,000 USD (as of September 11, 2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: SMI
